The data underlying this study contain sensitive patient information and cannot be made publicly available. The data have been deposited with the London School of Hygiene and Tropical Medicine's Data Compass and are accessible using the following DOI: <https://doi.org/10.17037/DATA.00001529>. Interested researchers wishing to request access to the data can do by clicking the "request access" button to fill a form which will be automatically submitted to the research data manager at London School of Hygiene and Tropical Medicine and to the first author. In addition, requests can be sent to <researchdatamanagement@lshtm.ac.uk>.

Introduction {#sec005}
============

Ghana is one of the tuberculosis (TB) and human immunodeficiency virus (HIV) high burden countries according to the World Health Organization (WHO) \[[@pone.0230604.ref001]\]. Ghana's TB case notification rate has declined from 56/100,000 in 2014 \[[@pone.0230604.ref002]\] to 52/100,000 in 2017\[[@pone.0230604.ref003]\] compared to an estimated incidence of 152/100,000 based on the 2013 national TB prevalence survey \[[@pone.0230604.ref004]\]. Ghana's national TB prevalence survey also highlighted weaknesses in the care cascade where of persons with prolonged cough who visited a health facility, only 25% submitted sputum for testing \[[@pone.0230604.ref004]\].

In Ghana, TB diagnosis and treatment is mainly done at government health facilities. Until recently, sputum smear microscopy was the main diagnostic method, but Xpert MTB/RIF has now been introduced with 105 GeneXpert machines installed nationwide by 2017 \[[@pone.0230604.ref003]\]. Most diagnostic laboratories are located at secondary and tertiary levels of care but not at peripheral levels such as health centres mostly in rural areas. Therefore, a person with symptoms of TB might be identified at a health centre but will have to travel themselves to the district hospital for a sputum test to confirm the diagnosis. This creates an obstacle to diagnosis and treatment and potential loss within the cascade of TB care.

There is a wealth of literature on health facility contribution to delayed or missed diagnosis of TB and pre-treatment loss-to-follow up \[[@pone.0230604.ref005]--[@pone.0230604.ref009]\]; however, most are cross-sectional studies involving TB patients already on treatment, thus excluding those who never started treatment, or retrospective reviews of secondary data \[[@pone.0230604.ref010]\]. To better understand losses from the care cascade, we conducted a prospective observational cohort study to identify where and when potential TB patients are missed in the diagnostic cascade. We hypothesized that distance to the laboratory was a key determinant of whether sputum was submitted or not, therefore, persons with symptoms suggestive of TB (presumptive TB patients) were less likely to submit a sputum if they attended a rural health facility without a laboratory compared to those attending an urban facility with a co-located laboratory. Our aim was to determine if persons asked to submit sputum for testing for TB submitted sputum, and whether this was associated with urban vs. rural location of the facility; also whether they received test results, and if the results were positive, whether they started TB treatment.

Materials and methods {#sec006}
=====================

Study setting {#sec007}
-------------

The study was conducted in Ketu South Municipality in the Volta region of Ghana, which shares boundaries with the Republic of Togo. The municipality has one government hospital and eight health centres. In 2017, the municipality notified 290 TB cases out of a target of 534 estimated based on the 2013 national TB prevalence survey. In 2018, it notified 172 TB cases out of a target of 546, indicating a decreased case detection rate from 53.8% in 2017 to 31.5% in 2018 \[[@pone.0230604.ref011]\]. There is only one TB diagnostic laboratory in the municipality, located at the municipal hospital. All other health facilities in the municipality refer patients with symptoms of TB to the municipal hospital for testing. The study was thus conducted in the municipal hospital, and four health centres without co-located TB diagnostic facilities in rural areas located 10 to 20 km from the municipal hospital. The four health centres were selected based on high outpatient department (OPD) attendance and to represent the different health demarcated sub-municipalities.

Study design {#sec008}
------------

This was a prospective observational cohort study among adults aged ≥18 years with or without symptoms suggesting TB, self-presenting at the health facility, who were identified routinely by a health worker as needing TB investigation and given a laboratory request to do a sputum test or referred to the municipal hospital.

### Sampling strategy {#sec009}

We consecutively invited eligible patients from the selected health facilities from May 2018 until the target study population had been enrolled in February 2019.

Data collection {#sec010}
---------------

At enrolment, trained research assistants collected baseline information on socio-demographic characteristics, symptoms of illness, health histories and date the sputum test was requested, using a standardised questionnaire. The questionnaire was pretested at the municipal hospital in a population similar to the study population. Following pretesting, revisions were made to improve comprehensibility and understanding. Participants were followed up for two months after the test request, via two-weekly phone calls to find out if sputum had been submitted, when and where it was submitted and the result of the test; and among those with a positive test result, to determine whether the patient had started TB treatment. Those without phones were visited at their homes once monthly for two months. Geographic positioning coordinates (GPS) of participant households and health facilities attended were collected. Coordinates were stored separately from participant information to ensure confidentiality. All data were collected electronically using Open Data Kit (ODK) and uploaded onto a secured server hosted by the London School of Hygiene & Tropical Medicine.

Sample size {#sec011}
-----------

Assuming 49% of participants attending an urban facility would submit sputum \[[@pone.0230604.ref007]\], we calculated that a sample size of 414 would provide 80% power to detect a difference of 15% in the proportion of participants who submitted a sputum in an urban versus a rural facility with alpha set to 5% and allowing 10% loss to follow up.

Measures and definitions {#sec012}
------------------------

TB symptoms were defined as the four cardinal symptoms of TB (cough, fever, weight loss and night sweats) and/or other TB symptoms (chest pain, coughing up blood, tiredness, shortness of breath and/or lump in neck). Rural and urban residence was defined based on the municipal health directorate categorization. Socioeconomic status was generated using asset scores which included 33 items, based on methods used by demographic and health surveys \[[@pone.0230604.ref012]\]. Participants' attitudes of stigma towards people with TB were measured using a tool developed by Van Rie et al, based on 12 questions measured on a five-point Likert scale, with 1 being lowest score for stigma and 5 being the highest \[[@pone.0230604.ref013]\]. The mean score across the 12 questions was calculated and dichotomized to represent high perceived or low perceived stigma. Distance from a participant's residence to the TB diagnostic facility was generated from GPS coordinates. Body mass index (BMI) was categorized according to WHO guidelines \[[@pone.0230604.ref014]\]. A Karnofsky score was estimated as a measure of illness severity \[[@pone.0230604.ref015]\]. Diabetes and HIV status were defined based on participant self-report.

### Primary outcome {#sec013}

This was the proportion of participants who submitted a sputum sample.

Data management and statistical analysis {#sec014}
----------------------------------------

Primary analysis assessed the causal effect of type of health facility attended (urban versus rural) on the probability of submitting sputum, using logistic regression. Any factor that changed the odds ratio by approximately 10% in bivariable analysis was considered a potential confounder and adjusted for in a final multivariable model. Kaplan-Meier analysis was used to compare the time to submitting sputum between urban and rural facility attendees. Predictive modelling was employed to assess risk factors associated with submitting sputum using logistic regression. Variables with likelihood ratio p-value \<0.2 in univariable analysis were included in a multivariable model. Data were analysed using Stata v15 (Stata Corp, College Station TX, USA).

Ethical considerations {#sec015}
----------------------

Ethical approval was obtained from the Ghana Health Service Ethics Review Committee and London School of Hygiene & Tropical Medicine Ethics Committee. Written informed consent was obtained from literate participants and for those who could not read and write, consent was documented with a thumbprint in the presence of a literate witness.

Results {#sec016}
=======

A total of 468 persons were approached: of this number 437 (93.4%) were eligible, 428/437 (97.9%) consented and were recruited (285 from urban facility and 143 from rural facilities). The main reason for non-eligibility was being \<18 years (28, 90.3%). Of the 428 recruited, 397 (92.8%) completed follow-up for two months, 13 (3.0%) died at some point in time within the two-month follow-up period and 17 (4.0%) were lost to follow up ([Fig 1](#pone.0230604.g001){ref-type="fig"}).

![Flowchart of study recruitment and follow up of people requested to give sputum for TB investigation in Ketu South Municipality, Ghana.](pone.0230604.g001){#pone.0230604.g001}

Baseline characteristics of study participants {#sec017}
----------------------------------------------

Among 428 participants, the mean age was 48 years (standard deviation \[SD\]18.8) and this was similar among urban and rural facilities ([Table 1](#pone.0230604.t001){ref-type="table"}). The majority of participants (288, 67.3%) were female and most (237, 55.4%) had attained primary level education. The median distance between participants' home and the laboratory was 17.3 km (interquartile range \[IQR\]16.7--19.4) for rural facility attendees and 2.6 km (IQR 1.3--10.0) for urban facility attendees. Most participants attending rural facilities were in the lowest socioeconomic tertile (58, 40.6%) compared to those attending urban facilities (85, 29.8%) and more than half (255, 59.6%) of study participants had a high perception of TB related stigma.

10.1371/journal.pone.0230604.t001

###### Baseline characteristics of participants (people requested to give sputum for TB investigation) in Ketu South Municipality, Ghana.

![](pone.0230604.t001){#pone.0230604.t001g}

  Characteristics                         Variable               Urban health facility, n = 285   Rural health facility, n = 143   Total, N = 428      P-value
  --------------------------------------- ---------------------- -------------------------------- -------------------------------- ------------------- ---------
  Age (years)                             Mean ± SD              47.6±17.9                        48.4±20.4                        47.9±18.8           0.901
  Gender                                  Male                   99 (34.7)                        41 (28.7)                        140 (32.7)          0.207
  Female                                  186 (65.3)             102 (71.3)                       288 (67.3)                                           
  Educational level                       No formal education    70 (24.6)                        34 (23.8)                        104 (24.3)          0.982
  Primary/JHS                             157 (55.1)             80 (55.9)                        237 (55.4)                                           
  Secondary/Tertiary                      58 (20.4)              29 (20.3)                        87 (20.3)                                            
  Place of residence                      Urban                  205 (71.9)                       1 (0.7)                          206 (48.1)          \<0.001
  Rural                                   80 (28.1)              142 (99.3)                       222 (51.9)                                           
  Distance to laboratory (km)             Median (IQR)           2.6 (1.3--10.0)                  17.3 (16.7--19.4)                10.0 (1.6--17.3)    \<0.001
  Socioeconomic status (tertiles)         High                   114 (40.0)                       28 (19.6)                        142 (33.2)          \<0.001
  Middle                                  86 (30.2)              57 (39.9)                        143 (33.4)                                           
  Low                                     85 (29.8)              58 (40.6)                        143 (33.4)                                           
  TB symptoms (yes)                       Cough                  279 (97.9)                       142 (99.3)                       421 (98.4)          0.279
  Fever                                   204 (71.6)             115 (80.4)                       319 (74.5)                       0.048               
  Night sweat                             70 (24.6)              24 (16.8)                        94 (22.0)                        0.067               
  Weight loss                             79 (27.7)              22 (15.4)                        101 (23.6)                       0.005               
  Symptoms duration (days)                Median (IQR)           19 (7--31)                       7 (7--14)                        14 (7--28)          \<0.001
  HIV status                              Positive               32 (11.2)                        0 (0.0)                          32 (7.5)            \<0.001
  Negative                                72 (25.3)              17 (11.9)                        89 (20.8)                                            
  Don't know                              181 (63.5)             126 (88.1)                       307 (71.7)                                           
  Diabetes                                No                     273 (95.8)                       142 (99.3)                       415 (97.0)          0.046
  Yes                                     12 (4.2)               1 (0.7)                          13 (3.0)                                             
  BMI (kg/m2)                             Median (IQR)           24.6 (19.7--34.1)                25.1 (22.0--30.3)                24.8 (20.3--32.6)   0.077
  Severity of illness (Karnofsky score)   Mean ± SD              81.2±10.8                        86.1±6.4                         82.9±9.8            \<0.001
  Stigma                                  Low perceived stigma   138 (48.4)                       35 (24.5)                        173 (40.4)          \<0.001
  High perceived stigma                   147 (51.6)             108 (75.5)                       255 (59.6)                                           

N = total number, n = number within facility, SD = standard deviation, IQR = interquartile range, BMI = body mass index, TB = tuberculosis, HIV = human immunodeficiency virus, JHS (13--15 years) = junior high school

Cascade of care {#sec018}
---------------

Of 410 presumptive TB patients asked to do a sputum test who were followed up, 290 (70.7%) submitted sputum for the test; 194/290 (66.9%) received a test result; 27/194 (13.9%) had a positive test result and all 27 started TB treatment ([Fig 2](#pone.0230604.g002){ref-type="fig"}). Sixteen additional patients started treatment based on chest radiograph findings. Stratifying by type of health facility attended, 245/267 (91.8%) submitted sputum among those attending the urban facility and 45/143 (31.5%) among those attending rural health facilities ([Fig 2](#pone.0230604.g002){ref-type="fig"}).

![Cascade of TB care among people requested to give sputum for TB investigation in Ketu South Municipality, Ghana.](pone.0230604.g002){#pone.0230604.g002}

Time to submitting sputum among rural and urban health facility attendees {#sec019}
-------------------------------------------------------------------------

In Kaplan-Meier analysis, there was strong evidence for a difference in time to submitting sputum by location of health facility, where urban facility attendees submitted sputum earlier than rural facility attendees (P\<0.001) ([Fig 3](#pone.0230604.g003){ref-type="fig"}). Of urban facility attendees, 229 (80.4%) submitted sputum on the day the test was requested, 10 (3.5%) submitted within 7 days and 6 (2.1%) after 14 days. However, among rural facility attendees, only 6 (4.2%) submitted sputum on the day the test was requested, 18 (12.6%) within 7 days and 21 (14.7%) after 14 days ([Fig 3](#pone.0230604.g003){ref-type="fig"}).

![Time from test request to submitting sputum for people requested to give sputum for TB investigation in Ketu South Municipality, Ghana.](pone.0230604.g003){#pone.0230604.g003}

Reasons for not submitting sputum {#sec020}
---------------------------------

The main reasons given by participants for not submitting sputum were being too busy to go to the laboratory (58/116, 50.0%), feeling well so not seeing the need to do the test (19, 16.4%), having no money to travel to do the test (17, 14.7%) and being unable to produce sputum (15, 12.9%).

Association between type of health facility attended and submitting sputum {#sec021}
--------------------------------------------------------------------------

In causal analysis, participants recruited from the urban health facility had a much higher odds (unadjusted odds ratio \[OR\] 24.24, 95% CI 13.84--42.51) of submitting sputum compared to those recruited at a rural health facility. Adjusting for distance from participants' residence to the laboratory resulted in the biggest reduction in the odds of submitting sputum, comparing urban and rural facility attendees (adjusted OR \[aOR\] 12.98, 95% CI 5.95--28.30) ([Table 2](#pone.0230604.t002){ref-type="table"}). After adjusting for all other confounders, in the final adjusted model, a strong association between attending the urban versus rural health facilities and submitting sputum remained (aOR 9.52, 95% CI 3.87--23.40) ([Table 2](#pone.0230604.t002){ref-type="table"}).

10.1371/journal.pone.0230604.t002

###### Causal analysis showing association between the type of health facility attended and submitting a sputum for a TB test, Ketu South Municipal---Ghana.

![](pone.0230604.t002){#pone.0230604.t002g}

  Association between type of health facility attended and submitting sputum   OR      CI             P
  ---------------------------------------------------------------------------- ------- -------------- ----------
  **Univariable+**                                                             24.25   13.84--42.51   P\<0.001
  Confounder adjustment                                                                               
  Adjusted for longer distance from residence to laboratory                    12.98   5.95--28.30    P\<0.001
  Adjusted for rural residence                                                 18.25   8.08--41.21    P\<0.001
  Adjusted for negative HIV status                                             22.07   12.35--39.44   P\<0.001
  Adjusted for high perceived stigma                                           22.46   12.73--39.61   P\<0.001
  Adjusted for increasing number of symptoms                                   22.64   12.85--39.88   P\<0.001
  **Final: adjusted for all of above**                                         9.52    3.87--23.40    P\<0.001

†bivariate analysis between type of health facility (rural or urban) and sputum submission as an outcome.

OR = odds ratio, CI = 95% confidence interval, P = p-value

Factors associated with submitting sputum among study participants attending an urban or rural health facility {#sec022}
--------------------------------------------------------------------------------------------------------------

In univariable analysis ([Table 3](#pone.0230604.t003){ref-type="table"}), rural versus urban residence (OR 0.08, 95% CI 0.05--0.15); longer travel distance to the laboratory (OR 0.06, 95% CI 0.03--0.11 for 10--20 km and OR 0.17, 95% CI 0.07--0.41 for \>20 km versus \<10 km); and high versus low perception of TB-related stigma (OR 0.39, 95% CI 0.24--0.62) were associated with a lower odds of submitting sputum. Prior TB treatment (OR 4.00, 95%CI 1.19--13.460); more reported symptoms (OR 2.87, 95% CI 1.47--5.59 for \>4 versus 1--2), longer symptom duration (OR 2.20, 95% CI 1.39--3.50 for \>14 versus ≤14 days); and visit to at least one care providers prior to current clinic visit (OR 3.18, 95% CI 1.88--5.10) were predictors of submitting sputum.

10.1371/journal.pone.0230604.t003

###### Factors associated with submitting sputum among study participants attending rural and urban health facilities in Ketu South Municipality, Ghana.
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                                                   N = 410                                                                                                  
  ------------------------------------------------ ---------------- -------------------- ---------------------------------------------- ------------------- ---------
  **Age group (years)**                                                                  [\*](#t003fn001){ref-type="table-fn"}0.689                         
  18--38                                           99/145 (68.3)    1                                                                                       
  39--59                                           107/150 (71.3)   1.15 (0.70--1.90)    0.567                                                              
  ≥60                                              84/115 (73.0)    1.26 (0.73--2.16)    0.403                                                              
  **Gender**                                                                             [\*](#t003fn001){ref-type="table-fn"}0.177                         
  Male                                             102/136 (75.0)   1                                                                   1                   
  Female                                           188/274 (68.6)   0.73 (0.46--1.16)    0.182                                          0.90 (0.48--1.69)   0.739
  **Educational level**                                                                  [\*](#t003fn001){ref-type="table-fn"}0.706                         
  No formal education                              65/96 (67.7)     1                                                                                       
  Primary/JHS                                      162/228 (71.1)   1.17 (0.70--1.96)    0.549                                                              
  Secondary/Tertiary                               63/86 (73.3)     1.31 (0.69--2.48)    0.414                                                              
  **Place of residence**                                                                 [\*](#t003fn001){ref-type="table-fn"}\<0.001                       
  Urban                                            182/197 (92.4)   1                                                                   1                   
  Rural                                            108/213 (50.7)   0.08 (0.05-.015)     \<0.001                                        0.41 (0.16--1.03)   0.058
  **Distance to laboratory (Km)**                                                        [\*](#t003fn001){ref-type="table-fn"}\<0.001                       
  \<10                                             184/197 (93.4)   1                                                                   1                   
  10--20                                           74/168 (44.1)    0.06 (0.03--0.11)    \<0.001                                        0.12 (0.05--0.33)   \<0.001
  \>20                                             32/45 (71.1)     0.17 (0.07--0.41)    \<0.001                                        0.29 (0.10--0.86)   0.025
  **Socioeconomic status (tertiles)**                                                    [\*](#t003fn001){ref-type="table-fn"}0.002                         
  Low                                              92/134 (68.7)    1                                                                   1                   
  Middle                                           86/138 (62.3)    0.76 (0.46--1.25)    0.272                                          0.59 (0.30--1.13)   0.113
  High                                             112/138 (81.2)   1.97 (1.12--3.45)    0.018                                          1.03 (0.47--2.24)   0.945
  **Ever treated for TB**                                                                [\*](#t003fn001){ref-type="table-fn"}0.008                         
  No                                               263/380 (69.2)   1                                                                   1                   
  Yes                                              27/30 (90.0)     4.00 (1.19--13.46)   0.025                                          2.02 (0.45--9.07)   0.359
  **Number of symptoms**                                                                 [\*](#t003fn001){ref-type="table-fn"}\<0.001                       
  1--2                                             34/56 (60.7)     1                                                                   1                   
  3--4                                             123/191 (64.4)   1.17 (0.63--2.16)    0.615                                          1.33 (0.60--2.96)   0.488
  \>4                                              133/163 (81.6)   2.87 (1.47--5.59)    0.002                                          2.00 (0.83--4.80)   0.12
  **Duration of symptoms (days)**                                                        [\*](#t003fn001){ref-type="table-fn"}\<0.001                       
  ≤14                                              158/245 (64.5)   1                                                                   1                   
  \>14                                             132/165 (80.0)   2.20 (1.39--3.50)    0.001                                          0.83 (0.43--1.62)   0.589
  **HIV status**                                                                         [\*](#t003fn001){ref-type="table-fn"}0.037                         
  Positive                                         28/28 (100.0)    1                                                                   1                   
  Negative                                         66/85 (77.7)     1.79 (1.02--3.15)    0.043                                          0.85 (0.40--1.83)   0.678
  Don't know[+](#t003fn002){ref-type="table-fn"}   196/297 (66.0)   \-                   \-                                             \-                  \-
  **Severity of illness (Karnofsky score)**                                              [\*](#t003fn001){ref-type="table-fn"}0.024                         
  Less severe (≥90)                                136/217 (62.7)   1                                                                   1                   
  Moderately severe (70--80)                       133/167 (79.6)   2.70 (1.24--5.92)    0.013                                          1.84 (0.68--4.98)   0.228
  Severe (≤60)                                     21/26 (80.8)     0.92 (0.17--5.10)    0.924                                          0.14 (0.01--2.28)   0.165
  **Number of previous care providers visited**                                          [\*](#t003fn001){ref-type="table-fn"}\<0.001                       
  0                                                173/272 (63.6)   1                                                                   1                   
  ≥1                                               117/138 (84.8)   3.18 (1.88--5.40)    \<0.001                                        2.05 (1.02--4.13)   0.045
  **Stigma**                                                                             [\*](#t003fn001){ref-type="table-fn"}\<0.001                       
  Low perception                                   134/164 (81.7)   1                                                                   1                   
  High perception                                  156/246 (63.4)   0.39 (0.24--0.62)    \<0.001                                        0.54 (0.30--0.98)   0.043

\*Log likelihood P-value,

^+^Omitted from model due to collinearity,

OR = odds ratio, aOR = adjusted odds ratio, P = p-value, JHS (13--15 years) = Junior high school

In predictive multivariable analysis, longer travel distance to the laboratory and high perception of TB-related stigma remained associated with a lower odds of submitting sputum ([Table 3](#pone.0230604.t003){ref-type="table"}).

Discussion {#sec023}
==========

In south-east Ghana, more than a quarter of presumptive TB patients never submitted a sputum, and non-submission of sputum was most strongly associated with longer distance to the laboratory. Studies from Zimbabwe, India and Tanzania have also reported high pre-diagnosis loss-to-follow, 25%, 30.4% and 44% respectively \[[@pone.0230604.ref016]--[@pone.0230604.ref018]\], and some studies, including one from Ghana, showed that attending rural health clinics and long travel distance were risk factors for delay or pre-diagnosis loss to follow-up \[[@pone.0230604.ref007], [@pone.0230604.ref010], [@pone.0230604.ref017], [@pone.0230604.ref019]\]. In contrast, pre-diagnosis attrition was lower in South Africa and China (5% and 11% respectively) \[[@pone.0230604.ref020], [@pone.0230604.ref021]\], perhaps because in South Africa, sputum specimens are transported free to a central laboratory for diagnosis.

TB-related stigma was independently associated with non-submission of sputum, consistent with findings from a study in India \[[@pone.0230604.ref022]\]. Several studies have reported high perception of TB-associated stigma \[[@pone.0230604.ref023]--[@pone.0230604.ref027]\], and specific actions are needed to counter this \[[@pone.0230604.ref028], [@pone.0230604.ref029]\].

An encouraging finding was that all patients with a positive TB result on their sputum were promptly put on treatment. This contrasts with a study of routine data from a regional hospital in Ghana in 2011 where pre-treatment loss-to-follow up was 38% \[[@pone.0230604.ref030]\], and a systematic review which found an 18% pre-treatment loss to follow-up in Africa \[[@pone.0230604.ref031]\]. The difference could be due to the presence of a "task-shifting officer", dedicated to TB screening and follow-up in our study hospital's main outpatient department, supporting the value of this role.

Mortality among study participants was high, with 3% documented to have died within two months of enrolment, which is high for a population of presumptive TB patients but supports data from Zimbabwe \[[@pone.0230604.ref032]\]. An additional, 4% of participants recruited were lost to follow-up, if all these had died, two-month mortality would have been 7%. This further emphasizes the need for better access to prompt diagnosis and treatment for TB and other conditions.

Findings from this study have both programmatic and health system implications. This study clearly shows there is a gap in the cascade between a sputum test being requested and sputum being submitted, particularly among persons attending rural health facilities, and this can be attributed to the distance people need to travel to submit a sputum. An effective specimen transport system might bridge the gap in the diagnostic cascade.

Limitations {#sec024}
-----------

The study was designed to be observational rather than interventional and so the follow-up calls aimed to find out whether the participant had given a specimen and/or started TB treatment rather than motivating them to give a specimen; however, follow-up calls could have prompted some participants to give a sputum specimen, and thus we may have underestimated the true pre-diagnostic delays or losses.

Strengths {#sec025}
---------

The prospective cohort design of our study allowed us to determine pre-diagnostic losses directly and explore the reasons for losses, whereas previous studies have been based on secondary data analysis, or recruited patients already on TB treatment, thus excluding those who never started treatment.

Conclusion {#sec026}
==========

Almost 30% of patients asked to give a sputum specimen for TB testing in Ketu South municipality, Ghana, did not submit sputum: this was primarily determined by longer distance to the TB diagnostic laboratory. Closing this gap in the TB diagnostic cascade is an important step in reducing treatment delay and reducing TB transmission.
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Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. In addition, please provide any details of pretesting of the questionnaire, if such pretesting took place, including the number of participants and where they were recruited from.

3\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Additional Editor Comments:

I have gone through this manuscript and also the comments of both the Reviewers. The Authors may need to address all comments raised by both the reviewers to add more value to this manuscript. My decision is Minor revision.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Recording of positive family history of TB is not mentioned. if that is available in the records that should be mentioned .

Also if TB was suspected as a complication of HIV has not been recorded although presence / absence of HIV has been noted.

Reviewer \#2: Comments to the authors:

The current study entitled "Where are patients missed in the tuberculosis diagnostic cascade? A prospective cohort study in Ghana" by Joyce B. Der et al. reported the possible reasons and to circumvents these in lower TB diagnosis rate in Ghana. They showed in the current study that distance of the diagnostic centers from the reporting center is the main hurdle to submit the sample for diagnosis. Although, the population study size chosen is moderate as well as the age and gender is somewhat biased. These could be managed at the time of patient recruitment. The study well is designed, executed and presented. Data are presented in legible manner and are easily understandable. Manuscript is well written. The authors tried to find the reasons behind the less reporting of the TB cases in a region of Ghana. They determined the casual link and suggested the measures to combat the problems. The information provided in the manuscript can be used to fill the gap that exist in the regions of Ghana and if followed may increase the cases of TB reporting and their diagnosis. These information's can also be used to increase the rate of TB diagnosis and its management in high TB burden areas of the Ghana. The manuscript is suitable and could be considered for publication in PLOS ONE.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Mohd Shariq

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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15 Feb 2020

PONE-D-19-34140: Where are patients missed in the tuberculosis diagnostic cascade? A prospective cohort study in Ghana: Der J et al

We thank the reviewers for their positive feedback and comments. Our responses to the comments are below:

Reviewers' comments:

Reviewer \#1

Comment: Recording of positive family history of TB is not mentioned. if that is available in the records that should be mentioned.

Response: Thank you for this comment. Unfortunately we did not collect information on positive family history of TB and therefore cannot include it.

Comment: Also if TB was suspected as a complication of HIV has not been recorded although presence / absence of HIV has been noted

Response: Thank you for the comment. We recruited people who were attending the general outpatients' department using a referral system through the task shifting officer who is responsible for screening people with symptoms of TB and referring them to the laboratory for a sputum test. People attending for HIV care who needed investigation for TB were referred through this system and some will have been included in our study. We asked participants to report their HIV status if they knew it, and as you say we have reported this. However we did not ask participants their route of referral and so we are unable to report how many participants were referred from the antiretroviral (ART) clinic to the task shifting officer.

Reviewer \#2

Comment: The current study entitled "Where are patients missed in the tuberculosis diagnostic cascade? A prospective cohort study in Ghana" by Joyce B. Der et al. reported the possible reasons and to circumvents these in lower TB diagnosis rate in Ghana. They showed in the current study that distance of the diagnostic centers from the reporting center is the main hurdle to submit the sample for diagnosis. Although, the population study size chosen is moderate as well as the age and gender is somewhat biased. These could be managed at the time of patient recruitment. The study well is designed, executed and presented. Data are presented in legible manner and are easily understandable. Manuscript is well written. The authors tried to find the reasons behind the less reporting of the TB cases in a region of Ghana. They determined the casual link and suggested the measures to combat the problems. The information provided in the manuscript can be used to fill the gap that exist in the regions of Ghana and if followed may increase the cases of TB reporting and their diagnosis. These information's can also be used to increase the rate of TB diagnosis and its management in high TB burden areas of the Ghana. The manuscript is suitable and could be considered for publication in PLOS ONE.

Response: Thank you for the positive feedback about our study. In relation to the comment on age and sex being somewhat biased, our study was designed to consecutively select patients with symptoms of TB who have been routinely asked by a health worker to do a sputum test. We believe the study participants were therefore representative of people being asked to give a sputum for a TB test. We respectfully disagree with the comment. We have not changed the manuscript.

Editorial points to be addressed:

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

Response: This has been done

Please include additional information regarding the survey or questionnaire used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a questionnaire as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. In addition, please provide any details of pretesting of the questionnaire, if such pretesting took place, including the number of participants and where they were recruited from.

Response: The questionnaires developed for this study will be deposited with London School of Hygiene and Tropical Medicine's (LSHTM) Data Compass and a link provided so anyone interested can have unrestricted access.

The questionnaire was pretested at the municipal hospital among adults aged 18 years or more routinely identified by a health worker as requiring a sputum TB test. A total of eight participants were recruited, 4 (50%) males and 4 (50%) females aged between 27-85 years (mean age: 55 year \[SD:18\]).

We have added two lines on pretesting of the questionnaire in the manuscript (line 117-120 on page 5) which read:

The questionnaire was pretested at the municipal hospital in a population similar to the study population. Following pretesting, revisions were made to improve comprehensibility and understanding.

We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Response: We wish to maintain that data will be deposited with the London School of Hygiene and Tropical Medicine's Data Compass. However, due to the presence of sensitive patient information in the dataset, access will be restricted. It is recommended that persons who wish to access the dataset should click on the DOI link and then click on the \'request access\' button to fill a form which will be automatically submitted to the research data manager at London School of Hygiene and Tropical Medicine and to the first author. However, a non-author email address for request of the dataset is <researchdatamanagement@lshtm.ac.uk>.
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Dear Dr. Der,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

HASNAIN SEYED EHTESHAM

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

This manuscript was reviewed by 2 reviewers who were experts in the field. One of the reviewers has asked questions about family history of TB which the Authors were unable to provide since this was not in their record and was not designed to be part of this study. The Reviewer 2 also had a small issue about age and sex information which was also not part of the original study. The issues about the questionnaire for the study has been addressed. The other important issue about the repository and deposition of data has been clarified and these will be deposited in the London School of Hygiene and Tropical Medicine's data compass. The manuscript is now recommended for publication.
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Dear Dr. Der:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff
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Prof HASNAIN SEYED EHTESHAM
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